SCIENTIFIC PROGRAM


IMMUNOTHERAPY BRIDGE 2016
Royal Continental Hotel, Naples, Italy
November 30th, 2016


09.30 AM Registration **


Session I Immunotherapy Beyond Melanoma
Chairpersons: Alfredo Budillon, Graham Pawelec

10.00 AM What we learned from immunotherapy in melanoma, Paolo A. Ascierto
10.20 AM Checkpoint inhibitors anti PD1/PDL1 in metastatic NSCLC, Vera Hirsh
10.40 AM Immunotherapy in recurrent and metastatic head and neck cancer, Lisa Licitra
11.00 AM Perspectives of Immunotherapy in advanced HCC, Bruno Daniele
11.20 AM Break **
11.35 AM Discussion on the best research studies on Immunotherapy Beyond Melanoma **
12.35 PM Symposium: "Future prospects of lung, kidney, and head-and-neck immunotherapy"
01.35 PM Lunch **


Session II - Immunotherapy in Oncology: Data from clinical trials
Chairpersons: Sergio Bracarda, Sabino De Placido

02.20 PM Symposium: Immuno-oncology: a new paradigm in the treatment of cancer
Chairperson: Paolo A. Ascierto
03.20 PM Emerging Role of Immunotherapy in Bladder Cancer, Joseph Kim
03.40 PM Update on immunotherapy in GU malignancies, Hans Hammers
04.00 PM Break **
04.15 PM Immunotherapy for Breast Cancer: Recent Clinical Trial Results, Rita Nanda
04.35 PM Immunotherapy in ovarian and endometrial cancer, Sandro Pignata
04.55 PM Discussion on the best research studies on Immunotherapy in Oncology: data from clinical trials **
05.55 PM Conclusions, Paolo A. Ascierto




ORAL COMMUNICATIONS





November 30th 2016
SESSION I - Immunotherapy beyond melanoma
Chairpersons: Alfredo Budillon, Graham Pawelec

11.35 AM Discussion on the best research studies on Immunotherapy Beyond Melanoma **
11.35 AM LOH as Rthe missing instabilityR potentially underlying the tumor immunogenicity: on the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
Melissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Donatello Gasparro, Francesco Leonardi, Enrico Maria Silini, Sebastiano Buti
12.05 AM Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine
Maria Tagliamonte, Annacarmen Petrizzo, Angela Mauriello, Antonio Luciano, Domenica Rea, Antonio Barbieri, Claudio Arra, Piera Maiolino, Marialina Tornesello, Gennaro Ciliberto, Franco M. Buonaguro, Luigi Buonaguro


SESSION II - Immunotherapy in oncology: data from clinical trials
Chairpersons: Sergio Bracarda, Sabino De Placido

04.55 PM Discussion on the best research studies on Immunotherapy in Oncology: data from clinical trials **
04.55 PM PET imaging of the PD-1/PD-L1 checkpoint
Michael Hettich, Friederike Braun, Gabriele Niedermann
05.25 PM Adenosine generation limits the ability of radiation therapy to elicit anti-tumor immunity by hindering recruitment and activation of CD103+ DCs
Erik Wennerberg, Aranzazu Mediero, Bruce Cronstein, Silvia Formenti, Sandra Demaria


** Not included in the CME accredited program

For information please contact info@melanomabridge.org